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Abstract
Cardiogenic shock is a life-threatening condition and mortality remains high if there 
is no response with medical therapy. Recently, short-term percutaneous mechanical 
circulatory support (pMCS) devices have increased in use for refractory cardiogenic 
shock. These devices can provide full treatment or bridging to long-term MCS devices 
if patients need long-term support. There are four types of well-known MCS devices 
including Impella (Abiomed, Danvers, MA), TandemHeart (CardiacAssist, Pittsburgh, 
PA), and extracorporeal membrane oxygenation (ECMO) and intra-aortic balloon pump 
for short-term and percutaneous application. In this chapter, we aim to discuss the physi-
ologic concept, clinical evidences and applications, indications-contraindications, com-
plications, and comparison of these most commonly used short-term pMCS devices for 
advanced heart failure.
Keywords: cardiogenic shock, mechanical circulatory support, intra-aortic balloon 
pump
1. Introduction
Orthotopic heart transplantation (OHT) still continues to be the gold standard treatment 
for advanced heart failure refractory in medical therapy [1]. However, limitations of organ 
donation cause rapid technological growth in the field of mechanical circulatory support. For 
patients who cannot have a heart transplant, another option may be a ventricular assist device 
(VAD). A ventricular assist device is a mechanical device implanted into the chest that helps 
in pumping blood from the ventricles to the body.
© 2018 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use,
distribution, and reproduction in any medium, provided the original work is properly cited.
VADs are commonly used as a temporary treatment for people waiting for a heart transplant. 
These devices are increasingly being used as a long-term treatment for people who have heart 
failure but are not eligible for a heart transplant.
The bridge-to-transplant strategy integrating with a long-term continuous-flow VAD has played 
a major role in providing circulatory support during the waiting period prior to transplantation.
Short-term mechanical circulatory support devices (MCS) provide good hemodynamic sup-
port for patients with cardiogenic shock and these devices are increasingly used as a bridge-to-
decision in patients with refractory cardiogenic shock [2]. Short-term mechanical circulatory 
support devices acutely improve hemodynamic conditions.
When cardiogenic shock is refractory to medical therapy, percutaneous mechanical circula-
tory support (MCS) should be considered. Subsequently, these patients might be bridged to 
durable MCS either as a bridge-to-candidacy/transplantation or as a destination therapy.
There are three types (Table 1) of well-known MCS devices including Impella (Abiomed, 
Danvers, MA), TandemHeart (CardiacAssist, Pittsburgh, PA), and extracorporeal membrane 
oxygenation (ECMO), for short-term and percutaneous application. Intra-aortic balloon 
pump is also uses for short-term support in cardiogenic shock with percutaneous way. These 
various devices can aid, restore, or maintain appropriate tissue perfusion before the develop-
ment of irreversible end-organ damage.
Here, we discuss the patient selection, current state, ongoing advances, and implantation 
techniques of these percutaneous MCS.
2. İABP
IABPs are the most widely used MCS devices since its introduction in the 1960s. The IABP is a 
balloon catheter, which is generally inserted into the aorta through the femoral artery (Figure 1). 
At the beginning of diastole, the balloon inflates and the device increases the coronary perfusion. 
IABP Impella TandemHeart ECMO
Insertion time 6–22 min 11–41 min 15–45 min 15–60 min







Duration of support 6 h to several weeks 6 h to several days 6 h to several days 6 h to several days
Leg ischemia 0.9% 3.9% 3.4–33% 18.8%
Bleeding 0.8% 13% Up to 59.8% 18%
MAP: mean arterial pressure, PCWP: pulmonary capillary wedge pressure.
Table 1. The types and the characteristics of the pMCS devices.
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By systole, the balloon deflates and left ventricular after-load reduces and increases the cardiac 
output. So the pump decreases the left ventricular stroke work, myocardial oxygen require-
ments, and increased cardiac output. In this manner, the balloon supports the heart indirectly. 
Since it is easy to insert, IABP is the most widely used form of mechanical circulatory support.
The indications for IABP usage are failure to wean from cardiopulmonary bypass, cardio-
genic shock, heart failure, and acute heart attack. Although IABP is mainly used for surgical 
patients, the pump can be used during high-risk interventional cardiology procedures.
During acute-decompensated heart failure, IABP may help in supporting a patient who is 
awaiting a heart transplant in initial period, but if the patients need longer time, another 
p-MCS device can be replaced or long-term LVAD implantation may be required because of 
its limited length of use.
Before 2012, the American and European guidelines supported that implantation of IABP in 
cardiogenic shock recommended as a class I; but, in the IABP-SHOCK II trial study, IABP 
was not found to be associated with reduction in 30-day mortality in cardiogenic shock [3]. 
American guidelines have downgraded the recommendation for usage of the IABP from 
Class I to IIa, and European guidelines to Class III. Both American and European guide-
lines endorse the usage of other mechanical-assist devices that provide more hemodynamic 
support.
Absolute contraindications for IABP use are aortic insufficiency, aortic dissection-aneurysm, 
sepsis, and severe coagulopathy. Atherosclerosis and arterial tortuosity and left ventricular 
outflow tract obstruction are relative contraindications for IABP placement.
Figure 1. İABP.




Impella is a pump which pulls blood from the left ventricle and expels into the ascending 
aorta (Figure 2). The system has a continuous-flow microaxial pump located at the distal end 
of the catheter. The device can be inserted via a standard catheterization procedure through 
the femoral artery. It is inserted into the left ventricle via a femoral cut down or through the 
axillary artery, and goes through the ascending aorta, across the valve and into the left ven-
tricle. This pump can produce a flow from 2.5 to 5.0 L/min. The principal feature mechanism 
of the device is to reduce the ventricular work, and to provide the circulatory support neces-
sary to allow heart recovery.
Unlike the IABP, the Impella device uses continuous axial flow and consequently does not 
require pressure timing or electrocardiographic timing, allowing for stable output despite 
arrhythmias.
The device is mainly used during high-risk percutaneous coronary interventions (PCI) and 
in cardiogenic shock that is resistant to medical management. The device can also be used to 
hemodynamic support for the patient with severe left-ventricular dysfunction undergoing 
catheter ablation of hemodynamic condition [4].
In the setting of CS, two small trials have been performed with the Impella 2.5 pMCS, both 
using IABP therapy as the control therapy. The ISAR-SHOCK (efficacy study of LV assist 
device to treat patients with cardiogenic shock) trial randomized 26 patients between IABP 
and the Impella 2.5 in the setting of CS complicating AMI. The primary endpoint was the 
Figure 2. İmpella.
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 difference in cardiac index after 30 min of support, and the trial showed a higher cardiac 
index in patients treated with Impella than with IABP. The overall mortality was 46% in both 
groups [5]. The IMPRESS in STEMI trial randomized between the IABP and Impella 2.5 in 
patients with cardiogenic pre-shock. This study was powered for a difference in left ventricu-
lar function. However, this trial was stopped prematurely due to a lack of enrollment after 21 
patients had been enrolled [6].
The Impella pump can also be used for ventricular support in patients who develop heart 
failure after heart surgery. The device can provide immediate support and restore the hemo-
dynamic stability for a period of up to 7 days, and this may allow time for creating a defini-
tive treatment strategy [7]. Hence, patients who are waiting for a donor can be supported as a 
bridge-to-heart transplant with Impella device.
The Impella RP is a type of Impella pump designed for the treatment of right ventricular fail-
ure that can be inserted through the femoral vein. The prospective RECOVER RIGHT study 
showed that the safe, easily deployed, and reliable pump resulted in good hemodynamic 
benefit in patients with life-threatening right heart failure [8].
The Impella pump is not appropriate in patients with mural thrombus in the left ventricle, a 
mechanical aortic valve, severe aortic valve stenosis or insufficiency, severe peripheral arte-
rial disease, significant right heart failure, combined cardiorespiratory failure, and atrial or 
ventricular sepal defect (including post-infarct VSD).
4. TandemHeart
The TandemHeart is a continuous-flow centrifugal-assist device placed percutaneous way. 
Cannulas are inserted through the femoral vein and advanced across the intra-atrial septum 
into the left atrium (Figure 3). The pump withdraws oxygenated blood from the left atrium 
and returns to the femoral artery via arterial cannulas. The pump is capable of delivering 
blood flow up to 5.0 L/min.
The TandemHeart is creating a left atrial-to-femoral artery bypass that provides hemody-
namic support during mainly high-risk coronary interventions and cardiogenic shock after 
cardiac surgery.
Among all other available percutaneous circulatory support options, only TandemHeart pro-
vides a steady supply of oxygenated blood to the body, while decompressing the left ventricle 
to reduce the work of the heart.
The device provides active hemodynamic support in patients who have little residual ventric-
ular function and also can remain implanted for up to 3 weeks. For these reasons, if patients 
in advanced heart failure is too sick for immediate LVAD placement or transplantation, the 
TandemHeart may serve as a bridge-to-recovery, LVAD placement (as a bridge-to-bridge), or 
even transplantation.
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5. ECMO (extra corporeal membrane oxygenation)
ECMO provides a temporary support for heart and lungs. ECMO maintains gas exchange 
as well as cardiac support, and is used in patients suffering from respiratory failure, cardiac 
failure, or both. It is used for patients who have reversible cardiopulmonary failure such as 
advanced heart failure, acute respiratory distress syndrome (ARDS), pulmonary embolism, 
septic shock syndrome, and multiple organ system failure.
Blood is drained from the body with an external pump; then blood goes through a membrane 
gas exchanger for oxygenation and returns to the patient’s circulation (Figure 4).
ECMO can be applied with three different ways such as veno-arterial, veno-venous, and cen-
tral way. Veno-arterial (VA) ECMO drains blood from right atrium via a femoral venous or 
a right internal jugular venous catheter and blood returns to the aorta via femoral arterial 
catheter. VA-ECMO provides cardiac as well as pulmonary support. Veno-arterial ECMO 
(VA-ECMO) is considered in patients with cardiopulmonary collapse and is used to support 
patients in cardiogenic shock [9]. In non-post-cardiotomy failure patients requiring urgent 
cardiac support, peripheral VA-ECMO through the femoral artery and vein is the most 
common approach. Peripheral VA-ECMO has limitations, including retrograde blood flow 
leading to inadequate LV decompression. To solve this problem, some centers utilize con-
current IABP [10] or Impella [11] support to reduce the LV after-load, and hence pulmonary 
edema. Veno-venous (VV) ECMO drains blood from the right atrium and blood returns to 
the right atrium through the femoral or jugular venous catheter. VV-ECMO requires good 
Figure 3. TandemHeart.
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cardiac function and mainly uses in isolated severe respiratory failure. Veno-venous ECMO 
is reserved for patients in isolated respiratory failure with no significant cardiac dysfunction. 
Central ECMO can be applied after cardiac surgery if the heart cannot be weaned from the 
heart-lung machine due to post-cardiotomy syndrome. Cannulas, which are inserted for heart 
lung machine, can be connected to the ECMO circuit and the sternum leaves open and patient 
can transfer to the ICU with ECMO support for healing period.
With cardiac failure, VA-ECMO is the preferred method because it provides urgent circula-
tory support with oxygenation in the event of sudden heart failure, thus preventing organ 
damage. For this reason, it may help to support a patient who is awaiting a heart transplant.
Among other devices, one advantage of ECMO is providing hemofiltration and dialysis. The 
connectors have been incorporated between the oxygenator outlet and pump inlet so that a con-
tinuous renal replacement therapy (CRRT) device can be attached to the extracorporeal circuit.
In a VA-ECMO setting, when the heart has recovered, but if the lungs are still poorly function-
ing, the native cardiac output bounces against the pumped blood, usually in the aortic arch 
region. Accordingly, the coronary arteries, and to a variable degree the supra-aortic vessel as 
well, are provided with hypoxic blood, heart, and brain are harmed. Upper extremity cyano-
sis has brought up the term “Harlequin syndrome.” Therapeutic options consist of a reloca-
tion of the arterial cannula in to right subclavian artery or aorta, or in converting the system 
into a VA-V-setting.
The healthcare team looking after patients on short-term percutaneous MCS aim to 
avoid any complications that may occur from being on these devices. Some of the more 
serious problems that may occur in these patients include: (1) bleeding especially from 
Figure 4. ECMO.
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gastrointestinal system and brain. This can be a very serious problem if the bleeding hap-
pens in their brain, lungs, insertion sites of cannulae, or from gastrointestinal system. 
The patients should be monitored very carefully by frequent physical examinations and 
lab tests to make sure there is no bleeding. If there is bleeding, then medications can be 
given to help the blood to stop. Sometimes, surgery is needed to stop the bleeding. Blood 
and other blood products (such as platelets) may also need to be given if blood counts 
drop too low. (2) Acute renal failure may sometimes occur due to inadequate blood flow 
to their kidneys. With dialysis, the kidney damage may get better. However, in some 
cases, patients may need dialysis for the rest of their life. (3) Systemic or localized infec-
tion is another risk for these patients  especiall from the insertion site. Infections in these 
patients can usually be treated with antibiotics. However, some infections can cause to get 
sick and more organ damages. (4) Leg ischemia is usually the most common problem in 
these patients due to insertion of the catheter or cannulas through the femoral vessels. In 
some cases, blood flow may be affected in lower extremity due to occlusion of the vessels 
and ischemia may occur. Doctors should always be aware of leg ischemia. If this happens, 
surgery may be needed to get blood flowing back down the leg. (5) Stroke: in patients on 
short-term p-MCS, stroke is another life-threating complication because of potential small 
blood clots. This can cause a stroke, and parts of the brain may be permanently damaged. 
Percutaneous MCS devices can also cause hemolysis and thrombocytopenia.
Mechanical circulatory support can prevent multi-organ failure and death in patients with 
advanced heart failure during waiting period. Long-term continuous-flow VAD has played 
a major role in providing circulatory support during the waiting period prior to transplanta-
tion, but long-term LVAD must be inserted through a thoracotomy or sternotomy, which can 
be hazardous and time consuming. For these reasons, patients in decompensated heart failure 
are best served by an initial period of stabilization with temporary devices.
Most series have combined a variety of temporary devices, but few long-term devices, and the 
evaluations have involved all patients with cardiogenic shock regardless of the indication for 
and the type of mechanical support and widely varying rates of recovery have been reported. 
There are four commonly used types of MCS available, which is temporary and percutaneous 
application. But the device choice and the implantation timing are not definitely established. 
Data regarding percutaneous MCS devices in cardiogenic shock are limited. A meta-analysis 
of three randomized trials comparing TandemHeart and Impella to IABP, TandemHeart and 
Impella were associated with higher cardiac index, higher mean arterial pressure, lower pul-
monary capillary wedge pressure, but increased bleeding complications and no difference in 
30-day mortality [12].
Another trial study showed that the Impella was not associated with decreased 30-day mor-
tality in cardiogenic shock compared to IABP [13]. Each device should be applied according 
to the patient’s condition and time for recovery, bridge-to-long-term devices, or bridge-to-
transplantation. Another treatment strategy for percutaneous MCS is that we may consider 
to switch one device with other one depending on the indication. IABP can be opted for first 
option in patient with cardiogenic shock due to easy availability and rapid insertion. An IABP 
is simple and safe to insert, but provides little active hemodynamic support and depends 
on residual left ventricular function to be effective. If patients have worse left ventricular 
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function, Impella, TandemHeart, or VA-ECMO can be quickly and easily inserted percutane-
ously and provide active hemodynamic support. During acutely depressed left-ventricular 
function, IABP may be the first treatment option for clinician, but if patients need more time 
for recovery or patients need stronger hemodynamic support IABP can switch to Impella or 
TandemHeart. If patients have respiratory failure along with cardiogenic shock, VA-ECMO 
should be opted first because it provides oxygenation and good cardiac support.
There are only limited studies available for survival of transplanted patients after percutane-
ous MCS. Jasseron et al. reported that transplantation was associated with a lower risk of mor-
tality, even if the overall survival rate and 1-year post-transplant survival rate were inferior 
in patient on VA-ECMO and they suggested that transplantation may be considered to be an 
acceptable primary therapy in selected patients on VA-ECMO [14].
Percutaneous MCS can also be used for the treatment of ventricular failure in the situation 
of acute allograft cardiac failure or post-transplant RV failure after cardiac transplantation.
Although each percutaneous MCS device has different working mechanisms, all of them can 
serve as a bridge-to-bridge or bridge-to-transplant strategy. Device selection or sequential 
application of percutaneous MCS should be managed according to the LV function, time for 
recovery, and patient’s conditions.
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